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patients with small cell lung, non-small cell lung, ovarian, 
and renal cancer in phase II tumor-specific cohorts.
Results Fourteen patients received carfilzomib dur-
ing dose escalation. The single dose-limiting toxicity at 
20/36 mg/m2 was grade 3 fatigue, establishing the MPD 
as the expansion and phase II dose. Sixty-five additional 
patients received carfilzomib at the MPD. Adverse events 
included fatigue, nausea, anorexia, and dyspnea. Carfil-
zomib PK was dose proportional with a half-life <1 h. All 
doses resulted in at least 80 % proteasome inhibition in 
blood. Partial responses occurred in two patients in phase 
I, with 21.5 % stable disease after four cycles in evaluable 
patients in the expansion and phase II cohorts.
Conclusion Carfilzomib 20/36 mg/m2 was well tolerated 
when administered twice weekly by 2–10-min IV infusion. 
At this dose and infusion rate, carfilzomib inhibited the 
Abstract 
Purpose Tolerability, pharmacokinetics (PK), pharmaco-
dynamics, and antitumor activity of carfilzomib, a selective 
proteasome inhibitor, administered twice weekly by 2–10-
min intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 
in 28-day cycles, were assessed in patients with advanced 
solid tumors in this phase I/II study.
Methods Adult patients with solid tumors progress-
ing after ≥1 prior therapies were enrolled. The dose was 
20 mg/m2 in week 1 of cycle 1 and 20, 27, or 36 mg/m2 
thereafter. The maximum tolerated dose or protocol-defined 
maximum planned dose (MPD) identified during dose 
escalation was administered to an expansion cohort and to 
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proteasome in blood but demonstrated limited antitumor 
activity in patients with advanced solid tumors.
Keywords Proteasome inhibitor · Carfilzomib · Solid 
tumors · Pharmacokinetics · Pharmacodynamics
Introduction
The anticancer activity of proteasome inhibition has been 
validated clinically with bortezomib, a reversible dipep-
tide boronate proteasome inhibitor that primarily targets 
chymotrypsin-like (CT-L) activity but also inhibits caspase-
like activity [1–3]. Studies have demonstrated the safety 
and efficacy of bortezomib in patients with hematologic 
malignancies, particularly multiple myeloma (MM) [4, 5], 
as well as mantle cell lymphoma [6], but have shown lim-
ited single-agent efficacy in solid tumors [7–10]. Preclinical 
data, including insufficient drug exposure beyond the exte-
rior surface of certain solid tumors [11], physiologic stress 
responses that enhance solid tumor cell survival, and protea-
some subunit composition that more closely resembles the 
immunoproteasome, have been cited to explain the limited 
clinical efficacy seen with bortezomib in solid tumors [12].
The selective proteasome inhibitor carfilzomib was 
recently approved in the USA for the treatment of relapsed 
and refractory MM [13]. Carfilzomib is an epoxyketone 
that is structurally and mechanistically distinct from bort-
ezomib. It irreversibly inhibits the CT-L activities of both 
the constitutive proteasome and the immunoproteasome 
with minimal off-target activity [14, 15]. Preclinical and 
clinical studies have demonstrated that carfilzomib, unlike 
bortezomib [16], can be dosed on consecutive days, leading 
to prolonged and more complete inhibition of the protea-
some [14, 17]. Stepped-up dosing and the infusion of carfil-
zomib intravenously over 2–10 min appeared to mitigate 
the infusion-like reaction seen with infusions of 1–2 min 
[17]. Mimicking the clinical dosing schedule, consecutive-
day dosing of carfilzomib in a human solid tumor xeno-
graft model demonstrated more effective antitumor activity 
than either bortezomib or carfilzomib dosed on days 1 and 
4 [14]. In addition, in a study that replicated the clinical 
pharmacokinetics of both agents, a 1-h pulse of carfilzomib 
was more potent than bortezomib at killing solid tumor cell 
lines [14]. Taken together, these observations suggested 
that carfilzomib may have greater antitumor activity than 
bortezomib in solid tumors.
In the phase I and phase II study reported herein 
(NCT00531284), we assessed safety, tolerability, and effi-
cacy of carfilzomib administered by 2–10-min IV infusion 
in patients with advanced solid tumors. The phase II tumor 
types were selected based on results from the phase I dose-
escalation portion and preclinical data.
Patients and methods
Study objectives
The primary objective of the phase I dose-escalation por-
tion of the study was to determine the maximum tolerated 
dose (MTD) of carfilzomib up to a maximum planned 
dose (MPD) of 20/36 mg/m2. The primary objective of 
the expansion (various tumor types) and phase II tumor-
specific portions was to determine the disease control 
rate [DCR = complete response (CR) + partial response 
(PR) + stable disease (SD)] as defined by RECIST 1.0 [18] 
after four cycles of treatment at the MTD or MPD. Second-
ary objectives included pharmacokinetics (PK) and phar-
macodynamics (PDn) of carfilzomib.
Patients 18 years or older with pathologically con-
firmed solid malignancies progressing after one or more 
prior regimens, and with evaluable or measurable disease 
according to the RECIST criteria, were eligible for the 
study. In addition, patients with NSCLC or ovarian cancer 
should have received one or more platinum-based chemo-
therapy regimens but three or fewer, or four or fewer total 
regimens, respectively, and SCLC patients three or fewer 
regimens. Renal cell cancer patients were required to have 
failed two or more prior regimens. Other eligibility crite-
ria included life expectancy of at least 3 months, Eastern 
Cooperative Oncology Group performance status of 0–2, 
hemoglobin ≥8 g/dl, absolute neutrophil count ≥1,000/
mm3, platelets ≥100,000/mm3, creatinine clearance 
(CrCl) >20 ml/min, bilirubin ≤1.5× upper limit of nor-
mal (ULN), and alanine transaminase (ALT) ≤3 × ULN. 
Patients with symptomatic brain metastases, comorbid 
severe medical conditions, New York Heart Association 
class III or IV congestive heart failure, acute active infec-
tion within 2 weeks of first dose, or neuropathy grade ≥2 
by National Cancer Institute Common Terminology Crite-
ria for Adverse Events (NCI CTCAE) v3.0 [19] at baseline 
were ineligible.
Institutional Review Board approval and written 
informed consent were obtained from each patient prior to 
any study-related procedure.
Study drug administration
Carfilzomib (Onyx Pharmaceuticals, Inc, South San Fran-
cisco, CA) was administered by intravenous infusion over 
2–10 min on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. 
For the phase I dose-escalation portion, the starting dose in 
all cohorts for days 1 and 2 of cycle 1 was 20 mg/m2, based 
on the tolerated dose identified in hematologic malignan-
cies [19]. On all remaining cycle 1 dosing days (days 8, 9, 
15, and 16) and in all subsequent cycles, carfilzomib was 
administered at a dose of 20 mg/m2 in cohort 1 (20/20 mg/m2), 
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27 mg/m2 in cohort 2 (20/27 mg/m2), and 36 mg/m2 in 
cohort 3 (20/36 mg/m2). Stepped-up dosing in cycle 1 and 
dexamethasone premedication were adopted to abrogate 
fever, chills and/or rigors, and dyspnea, all of which were 
infrequently observed during initial therapy in MM trials 
[17, 20–23]. Dexamethasone 4 mg (intravenous or oral) 
was administered prior to each carfilzomib dose for the first 
cycle and during subsequent cycles when indicated. Upon 
completion of 12 treatment cycles, patients had the option 
of enrolling in an open-label extension study, PX-171-010 
(NCT00884312).
Study design and determination of MTD
The phase I dose-escalation portion of the study followed 
the standard 3 + 3 design. Patients were enrolled at two 
sites in sequential cohorts of 3–6 patients each to establish 
the MTD. The MTD was defined as the highest dose up to 
the MPD at which at least one of six patients experienced 
treatment-related dose-limiting toxicities (DLT) during the 
first cycle. DLTs were defined as treatment-related ≥grade 
2 neuropathy with pain, ≥grade 3 non-hematologic toxic-
ity, grade 4 neutropenia or thrombocytopenia lasting 7 or 
more days, or thrombocytopenia with bleeding. Toxicity 
was graded according to NCI CTCAE v3.0 [19].
Once dose escalation was completed, an additional 
11 evaluable patients with assorted tumor types could 
enroll in the expansion cohort to receive carfilzomib at the 
MTD/MPD. In the phase II tumor-specific portion of the 
study, cohorts of patients with NSCLC, SCLC, ovarian can-
cer, and renal cancer were to be treated at the MTD/MPD 
utilizing a Simon two-stage design. Tumor types included 
in the phase II tumor-specific cohorts were selected based 




All patients who received at least one dose of study treat-
ment were evaluable for the safety analysis. After the ini-
tiation of carfilzomib, adverse events (AEs) were evaluated 
at each visit. Patients completed a comprehensive neuro-
logic evaluation and radiographic assessment of tumor bur-
den using computerized tomography (CT) at baseline and 
every 8 weeks for the first 24 weeks, then every 12 weeks 
thereafter or at treatment discontinuation. Patients who 
received at least one cycle of treatment and had both base-
line and post-baseline disease assessments were evaluable 
for efficacy. Treatment response was assessed according 
to RECIST 1.0 [18]. Patients with stable disease (SD) or 
an objective response (CR or PR) after two cycles contin-
ued treatment until disease progression or unacceptable 
toxicity.
Pharmacokinetics and pharmacodynamics
Pharmacokinetic properties of carfilzomib (maximum 
plasma concentration [Cmax], area under the plasma concen-
tration versus time curve from time 0 to infinity [AUC0–inf], 
elimination half-life [t1/2], volume of distribution at steady-
state [Vss], and plasma clearance [CLp]) were assessed 
for all patients in the phase I dose-escalation cohorts and 
for individuals at select sites in the expansion and phase 
II cohorts. Serial blood samples were collected on days 1 
and 16 of cycle 1 and day 16 of cycle 2 as follows: pre-
dose, immediately post-dose, and then at 5, 15, and 30 min, 
and 1, 2, and 4 h post-dose. Plasma samples for PK stud-
ies were assayed using validated liquid chromatography/ 
mass spectrometry with a lower limit of detection of 
0.10 ng/ml [17].
Pharmacodynamics was assessed for all patients in the 
phase I dose-escalation portion and patients at select sites 
in the expansion and phase II portions of the study. Whole 
blood was collected on day 1 of the first two cycles prior 
to and 1 h after infusion for measurement of proteasome 
activity in whole blood and peripheral blood mononuclear 
cells (PBMCs). CT-L activity was assessed using a fluoro-
genic substrate assay with succinyl–Leu–Leu–Val–Tyr–
AMC (LLVY) as previously described [15, 19].
Statistical analysis
Continuous and categorical data were summarized with 
descriptive statistics or frequencies and percentages, 
respectively. For the phase II tumor-specific portion, the 
Simon two-stage sample size calculation applied a null 
hypothesis objective response rate (ORR = CR + PR) 
of 2 % and an alternative hypothesis ORR of 15 %, with 
the type I error at 5 % and a power of 0.8. For stage 1, 11 
evaluable patients were to be enrolled in each of the four 
solid tumor cohorts. If one or more patients demonstrated 
an objective response (CR or PR), that cohort would pro-
ceed to the second stage and enroll a total of 37 evalu-
able patients. Because there were multiple study sites, over 
enrollment was permitted.
Pharmacokinetic parameters were estimated by non-
compartmental analysis using WinNonlin Enterprise Ver-
sion 5.2 (Pharsight Inc., Mountain View, CA). Dose propor-
tionality was assessed using a one-way analysis of variance 
(ANOVA) at α = 0.05 significance level, with Bonferroni’s 
multiple comparison for post-tests (SAS Institute, Inc., 
Cary, NC).




Fourteen patients were enrolled in the phase I dose-esca-
lation portion, and 65 patients were enrolled in the expan-
sion (n = 16) and phase II tumor-specific cohorts (n = 49) 
between September 2007 and December 2009. Patient 
demographics and baseline characteristics are presented 
in Table 1. Most patients were heavily pretreated, with a 
median of three (range 1–9) prior chemotherapy regimens.
In the phase I dose-escalation portion, a median of 2 
cycles (range 1–12) were administered. No patients had 
their carfilzomib dose reduced due to AEs. During dose 
escalation, one patient completed 12 cycles of therapy and 
rolled over into the open-label extension study PX-171-
010, nine of 14 patients (64.3 %) discontinued the study 
due to disease progression, two patients (14.3 %) discon-
tinued due to AEs, one patient (7.1 %) discontinued due to 
lack of clinical benefit, and one patient (7.1 %) withdrew 
consent.
In the expansion and phase II portions, a median of 
two cycles (range 1–12) were administered. Twenty-one 
patients (32.3 %) missed at least one carfilzomib dose 
due to AEs (29.2 %) or schedule conflict (3.1 %), and the 
carfilzomib dose was reduced for eight patients (12.3 %) 
due to AEs of elevated blood creatinine/decreased CrCl. 
Two patients completed 12 cycles of carfilzomib therapy 
and continued treatment in the extension study. Forty-
two patients (64.6 %) discontinued treatment due to dis-
ease progression, seven (10.8 %) discontinued due to an 
AE, four (6.2 %) withdrew consent, and 10 (15.4 %) cited 
“other” reasons for discontinuing.
DLT and MTD
No MTD was identified up to the MPD in the phase I 
dose-escalation portion. There were no DLTs in cohorts 1 
(n = 3) and 2 (n = 4). In cohort 3 (n = 7), a patient with 
gastric cancer experienced a single DLT (grade 3 fatigue) 
during cycle 1 at 20/36 mg/m2. Because no additional 
patients experienced DLTs at this dose level, 20/36 mg/m2, 
the MPD was recommended for the expansion and phase II 
tumor-specific portions.
Safety
All 79 patients received at least one dose of carfilzomib and 
were evaluable for safety, and all experienced at least one 
AE of any grade (Table 2).
In the phase I dose-escalation portion, the most com-
mon AEs were headache (42.9 %), fatigue (35.7 %), and 
hypokalemia (35.7 %). The AEs leading to discontinuation 
for two patients in the dose-escalation cohorts—aspiration 
pneumonia (one patient in cohort 2) and diarrhea (one 
patient in cohort 3)—were not among the most common 
treatment-related AEs overall.
The most frequently reported AEs of any grade in 
the expansion and phase II tumor-specific portions were 
fatigue (58.5 %), nausea (43.1 %), anorexia (40.0 %), and 
dyspnea (36.9 %) (Table 2). Grade ≥2 peripheral neuropa-
thy and any grade hepatotoxicity were not observed. Ten 
patients (15.4 %) experienced grade 3 lymphopenia with-
out clinical sequelae; other grade 3/4 AEs were infrequent. 
The most common carfilzomib-related AEs in the expan-
sion and phase II portions included fatigue (36.9 %), nau-
sea (32.3 %), anemia (21.5 %), and chills (21.5 %). Seven 
patients discontinued primarily due to the following AEs 
(one patient each): congestive heart failure, hyponatremia, 
infusion-related reaction, pneumonia/septic shock, spinal 
cord compression, malignant pleural effusion, and neuropa-
thy. There were four deaths on study or within 30 days of 
ending treatment, all due to PD. No deaths were considered 
related to carfilzomib.
Table 1  Baseline characteristics and treatment history
a
 Phase I dose-escalation other tumors included: (one patient each) 
colon, gastric, mesothelioma, oropharynx, pharyngeal, soft palate and 
tonsil, and sarcoma
b
 Expansion other tumors included: (two patients each) colon, endo-
metrial, esophageal, pancreas, and thyroid; and (one patient each) 
anal, cervical, gall bladder carcinoma, prostate, squamous cell carci-
noma, and vulvar
c
 Enrollment to phase II tumor-specific cohorts required 11 evalu-
able patients for stage 1 of the Simon two-stage design. None of the 
cohorts proceeded to stage 2: NSCLC and ovarian cohorts did not 
meet stage 2 criteria, and SCLC and renal cohorts were terminated 
before stage 1 enrollment was completed
Characteristics  
and treatment  
history




and phase IIc 
(n = 65)
Gender, n (%)
 Female 6 (43) 38 (59)
 Male 8 (57) 27 (42)
Age, years, median (range) 59.5 (36–75) 62 (41–87)
Tumor type, n
 Small cell lung 3 9
 Non-small cell lung 2 15
 Renal 1 10
 Ovarian 1 15
 Othera, b 7 16
Number of prior  
therapies, median  
(range)
3 (2–6) 3 (1–9)
 Prior platinum-based  
regimens, n (%)
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Pharmacokinetics and pharmacodynamics
Samples were collected from all 14 phase I dose-escalation 
patients and from 16 patients in the expansion and phase 
II tumor-specific cohorts. Patients with incomplete samples 
were excluded from PK calculations and dose-proportion-
ality assessments. At all doses, carfilzomib plasma concen-
trations declined rapidly following 2–10-min IV infusion; 
by 4 h after dosing, plasma levels were below the limit 
of detection in almost all patients (Fig. 1). Cmax and AUC 
increased proportionally across the three doses tested, and 
the half-life was approximately 1 h or less in all cohorts 
(Table 3).
One hour after administration of carfilzomib on day 
1 of cycle 2, proteasome CT-L activity in whole blood 
and PBMCs was inhibited by ≥80 % (Fig. 2). Median 
proteasome inhibition was 83.4 % (range 82.9–85.5 %), 
91.6 % (range 79.0–93.2 %), and 88.6 % (range 
54.7–99.4 %) with carfilzomib 20, 27, and 36 mg/m2, 
respectively. Minimal recovery of constitutive protea-
some activity was observed between cycles in whole 
blood, but there was recovery in PBMCs by the start of 
the second cycle.
Antitumor activity
Twelve of 14 patients (85.7 %) in the phase I dose-escala-
tion portion and 51 of 65 patients (78.5 %) in the expan-
sion and phase II tumor-specific cohorts were evaluable 
for response. Two patients in the dose escalation and 14 
patients in the expansion and phase II tumor-specific 
cohorts (17.7 % overall) either did not have a post-baseline 
disease assessment, received less than one cycle of therapy, 
or both.
In the phase I dose-escalation portion, PR was con-
firmed in two patients treated with carfilzomib at 
Table 2  Most common adverse events and treatment-related adverse events













Any adverse event, n (%) 3 (100) 4 (100) 7 (100) 65 (100)
 Fatigue 0 2 (50.0) 3 (42.9) 38 (58.5)
 Nausea 0 0 4 (57.1) 28 (43.1)
 Anorexia 0 0 2 (28.6) 26 (40.0)
 Dyspnea 0 0 1 (14.3) 24 (36.9)
 Diarrhea 1 (33.3) 0 3 (42.9) 18 (27.7)
 Vomiting 0 0 4 (57.1) 18 (27.7)
 Pyrexia 0 0 3 (42.9) 18 (27.7)
 Chills 0 0 2 (28.6) 18 (27.7)
 Anemia 0 1 (25.0) 1 (14.3) 17 (26.2)
Any Grade 3/4 adverse event, n (%) 1 (33.3) 2 (50.0) 5 (71.4) 44 (67.7)
 Lymphopenia 0 1 (25.0) 3 (42.9) 10 (15.4)
 Anemia 0 1 (25.0) 0 4 (6.2)
 Fatigue 0 0 1 (14.3) 4 (6.2)
Any treatment-related adverse  
event, n (%)
2 (66.7) 2 (50.0) 6 (85.7) 58 (89.2)
 Fatigue 0 2 (50.0) 3 (42.9) 24 (36.9)
 Nausea 0 0 4 (57.1) 21 (32.3)
 Vomiting 0 0 4 (57.1) 12 (18.5)
 Anemia 0 0 1 (14.3) 14 (21.5)
 Chills 0 0 1 (14.3) 14 (21.5)
Any grade 3/4 treatment-related adverse 
event, n (%)
0 0 2 (28.6) 20 (30.8)
 Lymphopenia 0 0 1 (14.3) 6 (9.2)
 Anemia 0 0 0 4 (6.2)
 Hypophosphatemia 0 0 0 3 (4.6)
 Renal failure acute 0 0 0 2 (3.1)
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20/36 mg/m2. A patient with renal cancer who had failed 
two multi-targeted antiangiogenesis inhibitors and an 
mTOR inhibitor had a >80 % reduction in tumor burden 
after five cycles of carfilzomib and continued on therapy 
for 13 cycles until disease progression with a dural-based 
brain metastasis. A patient with SCLC who had received 
six prior chemotherapy regimens had a durable PR with 
carfilzomib and remained on treatment for 39 cycles until 
disease progression. Two additional patients achieved SD, 
and eight patients had PD.
Among the 51 evaluable patients in the expansion and 
phase II tumor-specific cohorts, 48 (94.1 %) had measur-
able disease according to RECIST criteria. No patients 
achieved PR or better after four cycles of therapy or over 
the study period. However, 22 patients (43.1 %) had SD 
after two cycles and 11 of these patients had SD over four 
cycles (primary endpoint, overall DCR = 21.5 %). Of 
four patients with SD for 6 months or longer, two patients 
with renal clear cell carcinoma had SD for 6 months, a 
patient with NSCLC had SD for 10 months, and a patient 
with ovarian cancer had 12 months of SD. PD was the 
best response in all other expansion and phase II patients 
(29/51, 56.9 %). None of the phase II tumor-specific 
cohorts proceeded to stage 2 enrollment. Maximum per-
cent change in radiographic assessment of target lesions 
for dose expansion and phase II patients is shown in 
Fig. 3.






























Fig. 1  Plasma concentration versus time profiles for carfilzomib. 
Plasma concentration of carfilzomib at various time points after a 


































































Cohort 3 + 
Expansion + 
Phase 2
Blood PBMCbaFig. 2  Proteasome activity 
in whole blood and periph-
eral blood mononuclear cells. 
Chymotrypsin-like-specific 
proteasome activity in whole 
blood (a) and PBMCs (b) prior 
to and 1 h after the first dose 
in cycle 2 using LLVY-AMC 
substrate. Data are presented 
as mean activity (±SEM) rela-
tive to cycle 1 day 1 predose 
samples. (c) cycle; (d) day; pre, 
pre-dose
Table 3  Pharmacokinetic parameters of carfilzomib in cycle 1
a




 Arithmetic mean ± SD
d
 t1/2, Vss, CL n = 23
e
 AUCinf, t1/2, Vss, CL n = 4
f
 Includes 1 patient from the phase 2 20/36 cohort whose dose was reduced
g
 t1/2, Vss, CL n = 10
Days Dose (mg/m2) N Cmax (ng/mL)a t1/2 (h)b CL (L/h)c Vss (L)c AUClast (ng h/mL)a
1 20 30d 2390 ± 104 0.44 (0.15–2.20) 263 ± 398 27.7 ± 48.6 251 ± 92.0
16 20 3 3410 ± 51.5 1.10 (1.00–1.13) 136 ± 52.8 7.75 ± 3.77 269 ± 61.7
16 27 5e, f 4232 ± 48.8 0.35 (0.26–0.92) 150 ± 30.9 11.1 ± 4.45 379 ± 24.8
16 36 13g 5718 ± 46.5 0.87 (0.38–1.81) 116 ± 48.6 9.33 ± 4.80 594 ± 52.5
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Discussion
In the current study, carfilzomib was safely administered 
by 2–10-min intravenous infusion at the MPD of 20/36 mg/
m2 in patients with advanced solid malignancies. This dose 
exceeds that of 20/27 mg/m2 determined as the tolerable 
dose for 2–10-min intravenous infusion in patients with 
MM [17, 20–23]. Although all patients experienced AEs, 
carfilzomib was generally well tolerated with few patients 
reducing the dose or discontinuing therapy due to AEs. 
Mild or moderate non-hematologic AEs including fatigue, 
nausea, and anorexia were most common and similar to 
AEs observed in patients with MM [17, 20–23]. Notable 
in these pretreated patients, many with prior taxane and 
platinum-based therapy exposure, was the absence of treat-
ment-emergent grade ≥2 peripheral neuropathy, consistent 
with earlier observations [20–23]. In contrast to results in 
patients with MM, cardiopulmonary, hepatic, and renal tox-
icities were not common in patients with solid tumors.
The primary endpoint of the expansion and phase II 
tumor-specific portions of the study was DCR after four 
cycles. Although no patients achieved PR or better during 
this part of the study, 11 of 51 evaluable patients (21.5 %) 
with advanced solid tumors experienced SD after four 
cycles of carfilzomib, with four of these patients achieving 
SD for 6 months or more.
Despite demonstrating significant proteasome inhibi-
tion in surrogate tissue at the highest dose tested (36 mg/
m2) and PK results consistent with previous observations, 
the efficacy results seen in patients with advanced solid 
tumors differ from the robust antitumor activity seen with 
lower doses of carfilzomib in MM [20–23]. As noted, the 
proteasome inhibitor bortezomib has shown disappointing 
single-agent activity and limited activity in combination 
regimens in a variety of solid tumors [7–10, 24]. Despite a 
large volume of distribution, it is possible that carfilzomib 
does not effectively penetrate solid tumors when infused 
over 2–10 min, especially given its rapid systemic clear-
ance and very short elimination half-life. Proteasome inhi-
bition in PBMCs was rapid and prolonged; however, the 
PBMCs likely do not represent the amount of inhibition 
within the tumor cells. It is also possible that, despite irre-
versible binding of carfilzomib to the proteasome, recov-
ery of proteasome activity between doses was sufficient to 
permit survival of solid tumor cells. Antitumor activity in a 
small number of patients suggests that effective levels were 
achieved in some tumors or that some tumors were more 
sensitive to the effects of proteasome inhibition. Future 
studies with paired pre- and post-treatment tumor biopsies 
may provide a more accurate determination of the amount 
and duration of proteasome inhibition within the tumor, 
reveal mechanisms of resistance, and assist in identifying 
biomarkers predictive of response to carfilzomib in solid 
tumors.
The stipulation of a protocol-defined MPD restricted 
further dose escalation, which may have contributed to the 
low response rate. The design of the current study and pre-
specified MPD was based on the safety and efficacy data 
generated from a phase 1 trial of carfilzomib in patients 
with hematologic malignancies [17]. In that study, carfil-
zomib was well tolerated, but doses >20/27 mg/m2 were 
not explored. As there was concern regarding tolerability of 
higher doses and since the PD endpoint of >90 % protea-
some inhibition was achieved in PMBCs at 20/27 mg/m2 
[17], the decision was thus made to define a MPD of 
20/36 mg/m2 for this study. While the study was ongoing, 
emerging preclinical data suggested that a longer infusion 
time might result in better tolerance and allow adminis-
tration of higher doses of carfilzomib over longer periods, 
with potential for greater and more prolonged proteasome 
inhibition and improved efficacy [25]. With the phase II 
NSCLC and ovarian cohorts not meeting criteria to pro-
ceed to the second stage, and the low likelihood that criteria 
would be met in the remaining two tumor-specific cohorts, 
patient accrual was terminated to pursue a currently ongo-
ing exploration of a 30-min intravenous infusion.
In summary, the MPD of carfilzomib, 20/36 mg/m2, was 
well tolerated when administered by 2–10-min IV infusion 
on a twice weekly schedule. At this dose and infusion rate, 
carfilzomib demonstrated a PK profile consistent with pre-
vious reports in patients with MM and inhibited the protea-
some in blood, but demonstrated limited antitumor activ-
ity in patients with advanced solid tumors. The tolerable 
Fig. 3  Maximum reduction in target lesions in expansion and 
phase II patients. Percentage change in target lesion from baseline 
as assessed by CT scan. According to RECIST criteria, best overall 
responses are assigned after confirmation in a subsequent scan after 
≥4 weeks; therefore, maximum decrease in target lesion may differ 
from best overall response. Presented are the 48 patients treated at 
the MTD in the expansion and phase II portions, with measureable 
disease evaluable by RECIST. Solid lines represent thresholds for 
response: 20 % increase for progressive disease and 30 % decrease 
for partial response. NSCLC, non-small cell lung cancer; SCLC, 
small cell lung cancer; OVCC, ovarian cancer; RCC, renal cell cancer
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AE profile—in particular, the lack of clinically meaning-
ful peripheral neuropathy with carfilzomib—provides the 
opportunity for combination studies with other cytotoxic 
or targeted agents that might leverage the additive or syn-
ergistic effects of proteasome inhibition. Whether higher 
doses and/or combinations with cytotoxic or targeted 
agents could lead to improved efficacy with an acceptable 
safety profile remains an open question worthy of further 
investigation.
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